- Home
- INKT vs ANEB Comparison
INKT vs ANEB Comparison
Compare INKT & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ANEB |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 96.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INKT | ANEB |
|---|---|---|
| Price | $11.91 | $2.17 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 19.9K | ★ 20.6K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.56 | $0.80 |
| 52 Week High | $76.00 | $3.42 |
Technical Indicators
Market Signals| Indicator | INKT | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 41.98 |
| Support Level | $11.55 | $1.91 |
| Resistance Level | $12.68 | $2.40 |
| Average True Range (ATR) | 0.83 | 0.14 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 31.54 | 51.77 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.